Eli Lilly's Tirzepatide shows reductions in blood sugar levels and weight
Drug candidate Tirzepatide for treating type II diabetes has shown significant reductions in average long-term blood glucose levels, A1C, and body weight, according to new Eli Lilly data.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
New data from US pharmaceutical company Eli Lilly shows significant reduction in long-term blood sugar levels, A1C, and the body weights of patients when using the firm's drug candidate Tirzepatide's highest dose at 15 mg, according to an Eli Lilly press release on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Teva plans to take over major chunk of migraine market
For subscribers
